Recent Advances in Mesothelioma Treatment: Immunotherapy, Advanced Cell Therapy, and Other Innovative Therapeutic Modalities

Our plain-English summary of Recent Advances in Mesothelioma Treatment: Immunotherapy, Advanced Cell Therapy, and Other Innovative Therapeutic Modalities, by R. Suraya, T. Nagano, M. Tachihara (Cancers, 2025).

The study

• Authors: R. Suraya, T. Nagano, M. Tachihara
• Journal: Cancers
• Published: 2025;17(4)
• Type of article: Review
• Cited by: 6 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Mesothelioma is a highly malignant condition arising from the pleura and peritoneum that is closely related to asbestos exposure. The prognosis for this condition has traditionally been poor due to the difficulty physicians have faced in diagnosing and treating this disease, even in its early phase. Fortunately, recent advances in both the molecular understanding of the development of this disease and innovative and novel treatment modalities have accelerated the discovery of new ways to treat mesothelioma. In this review, we first summarize the mechanism of mesothelioma pathophysiology and then relate it to emerging treatment modalities. These include immunotherapy or immune checkpoint inhibitors (ICIs), molecular targeted therapies, and cell-based therapies (such as CAR-T cells or dendritic cells). The scientific basis for the utilization of these treatment modalities, alongside the current clinical evidence for each option, will be explored in detail later on. The hope is that this review can elucidate how these emerging therapeutic options work clinically to help accelerate further developments in novel mesothelioma treatment modalities.

In plain English

This was a review article by three authors at Kobe University in Japan. It did not study new patients. The authors first summarized how mesothelioma is thought to develop. They described the disease as arising from the pleura and peritoneum and as closely related to asbestos exposure. They then described published clinical trials of newer treatments: immune checkpoint inhibitor drugs, molecular targeted drugs, cell-based therapies such as CAR-T cells and dendritic cells, and other approaches such as tumor-treating fields. The review stated that the only newer options approved for clinical use were nivolumab plus ipilimumab, nivolumab alone (in Japan), and tumor-treating fields. As the review reported it, the CheckMate-743 trial of 713 patients with previously untreated, unresectable mesothelioma found a median overall survival of 18.1 months with nivolumab plus ipilimumab versus 14.1 months with chemotherapy. Some trials it described had less favorable results. In the DETERMINE trial, for example, survival with tremelimumab (7.7 months) and with placebo (7.3 months) was not significantly different. The authors concluded that new treatments, especially immunotherapies, are starting to emerge and to be proven useful in clinical studies.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published research on mesothelioma treatment; the article does not describe how studies were searched for or selected
• Who was studied: No patients were studied directly. The review covered published clinical trials of mesothelioma treatments. Authors from the Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Japan
• Exposure: Not an asbestos exposure study. The 'exposures' reviewed were treatments: immune checkpoint inhibitors, molecular targeted therapies (VEGF, mesothelin, PARP and EZH2 inhibitors), cell-based therapies (CAR-T cells, dendritic cells), and others (TargomiR, pegargiminase, stromal cell-assisted paclitaxel delivery, tumor-treating fields). Asbestos was mentioned only as background, citing other work
• Main results:
  • The review stated that the only newer treatment options approved for clinical use were nivolumab plus ipilimumab, nivolumab alone (in Japan), and tumor-treating fields
  • As reported by the review, the CheckMate-743 trial (713 patients with previously untreated, unresectable mesothelioma) found a median overall survival of 18.1 months with nivolumab plus ipilimumab versus 14.1 months with chemotherapy
  • As reported by the review, in the DETERMINE trial (571 previously treated patients), median overall survival was not significantly different between tremelimumab (7.7 months) and placebo (7.3 months)
  • As reported by the review, the MAPS trial found a median overall survival of 18.8 months with bevacizumab added to cisplatin and pemetrexed versus 16.1 months with chemotherapy alone
  • As reported by the review, in the DENIM trial, median overall survival was 16.8 months in the dendritic cell arm versus 18.3 months in the best supportive care arm
  • As reported by the review, in the STELLAR trial, 80 patients treated with tumor-treating fields plus chemotherapy had a median overall survival of 18.2 months. Skin reactions occurred in 71% of patients
• The authors' conclusion: The authors concluded that new treatment strategies, especially immunotherapies, are starting to emerge and to be proven useful in clinical studies, and that other approaches are still being developed

Topics

Medical terms in this study, explained in our Lexicon: Mesothelioma, Immunotherapy, Pleura, Peritoneum, Asbestos Exposure, Prognosis, Discovery, checkpoint inhibitors.

Related studies

• Recent advances in the treatment of malignant pleural mesothelioma — S.S. Ramalingam, C.P. Belani (2008)
• Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies — L. Chiec, D.S. Bruno (2024)
• Dendritic Cells in Human Lung Disease: Recent Advances — J.W. Upham, Y. Xi (2017)
• Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review) — E. Rijavec, F. Biello, et al. (2022)
• Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples — S. Monaco, M. Mehrad, et al. (2018)
• Recent advances in pulmonary cytopathology — S.D. Greenberg (1983)

Browse more research in Cancers, or return to medical research.